ERBB2 and breast cancer: In stage B, HR+/HER2+ breast cancer shows the best 5-year distant recurrence-free survival rate, followed by HR+/HER2− breast cancer, HR−/HER2+ breast cancer, and HR−/HER2− breast cancer.